38 research outputs found
Web-based patient-reported outcomes using the International Consortium for Health Outcome Measurement dataset in a major German university hospital: observational study
Background: Collecting patient-reported outcome (PRO) data systematically enables objective evaluation of treatment and its related outcomes. Using disease-specific questionnaires developed by the International Consortium for Health Outcome Measurement (ICHOM) allows for comparison between physicians, hospitals, and even different countries. Objective: This pilot project aimed to establish a digital system to measure PROs for new patients with breast cancer who attended the Charité Breast Center. This approach should serve as a blueprint to further expand the PRO measurement to other disease entities and departments. Methods: In November 2016, we implemented a Web-based system to collect PRO data at Charité Breast Center using the ICHOM dataset. All new patients at the Breast Center were enrolled and answered a predefined set of questions using a tablet computer. Once they started their treatment at Charité, automated emails were sent to the patients at predefined treatment points. Those emails contained a Web-based link through which they could access and answer questionnaires. Results: By now, 541 patients have been enrolled and 2470 questionnaires initiated. Overall, 9.4% (51/541) of the patients were under the age of 40 years, 49.7% (269/541) between 40 and 60 years, 39.6% (214/541) between 60 and 80 years, and 1.3% (7/541) over the age of 80 years. The average return rate of questionnaires was 67.0%. When asked about the preference regarding paper versus Web-based questionnaires, 6.0% (8/134) of the patients between 50 and 60 years, 6.0% (9/150) between 60 and 70 years, and 12.7% (9/71) over the age of 70 years preferred paper versions. Conclusions: Measuring PRO in patients with breast cancer in an automated electronic version is possible across all age ranges while simultaneously achieving a high return rate
Betriebsmittelliste 2010 fĂĽr die Schweiz
Die Betriebsmittelliste beinhaltet alle für den biologischen Landbau in der Schweiz zugelassenen Dünger und Substrate, Pflanzenschutzmittel, Reinigungs-, Desinfektions- und Hygienemittel, Mittel gegen Parasiten sowie Futter- und Siliermittel. Die Liste ist für die Produzenten von Bio Suisse verbindlich. Grundsätzlich dürfen auf Bio Suisse-Betrieben ausschliesslich die in der Betriebsmittelliste aufgeführten Produkte eingesetzt werden. Ausnahmen sind in den Einleitungen der einzelnen Kapitel vermerkt
Liste des intrants 2018
La liste des intrants contient tous les produits phytosanitaires, les engrais, les substrats du commerce, les produits de lutte contre les mouches des étables, les agents d'ensilage, les aliments minéraux et complémentaires, les produits pour la désinfection des stabulations et les produits contre les maladies des abeilles autorisés pour l'agriculture biologique. Cette liste est contraignante pour les producteurs de Bio Suisse et Demeter. Sur les fermes Bio Suisse, seuls les produits mentionnés sont autorisés. Les exceptions sont décrites séparément dans les introductions aux différents chapitres
Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants
The Swiss Preschoolers’ health study (SPLASHY): objectives and design of a prospective multi-site cohort study assessing psychological and physiological health in young children
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Liste des intrants 2015
La liste des intrants contient tous les produits phytosanitaires, les engrais, les substrats du commerce, les produits de lutte contre les mouches des étables, les agents d'ensilage, les aliments minéraux et complémentaires, les produits pour la désinfection des stabulations et les produits contre les maladies des abeilles autorisés pour l'agriculture biologique. Cette liste est contraignante pour les producteurs de Bio Suisse. Sur les fermes Bio Suisse, seuls les produits mentionnés sont autorisés. Les exceptions sont décrites séparément dans les introductions aux différents chapitres
Betriebsmittelliste 2015 fĂĽr die Schweiz
Die Betriebsmittelliste beinhaltet alle für den biologischen Landbau in der Schweiz zugelassenen Dünger und Substrate, Pflanzenschutzmittel, Reinigungs-, Desinfektions- und Hygienemittel, Mittel gegen Parasiten sowie Futter- und Siliermittel. Die Liste ist für die Produzenten von Bio Suisse verbindlich. Grundsätzlich dürfen auf Bio Suisse-Betrieben ausschliesslich die in der Betriebsmittelliste aufgeführten Produkte eingesetzt werden. Ausnahmen sind in den Einleitungen der einzelnen Kapitel vermerkt. Der Einsatz von Pflanzenschutzmitteln, Düngern, Futter- und anderen Betriebsmitteln in Schweizer Biolandwirtschaftsbetrieben ist in der “Bio-Verordnung“ und der entsprechenden Verordnung des Eidgenössischen Departements für Wirtschaft, Bildung und Forschung geregelt
Betriebsmittelliste 2020 fĂĽr den biologischen Landbau in der Schweiz
Die Betriebsmittelliste beinhaltet alle für den biologischen Landbau in der Schweiz zugelassenen Dünger und Substrate, Pflanzenschutzmittel, Reinigungs-, Desinfektions- und Hygienemittel, Mittel gegen Parasiten sowie Futter- und Siliermittel. Die Liste ist für die Produzenten und Produzentinnen von Bio Suisse und Demeter verbindlich. Grundsätzlich dürfen auf Bio Suisse-Betrieben ausschliesslich die in der Betriebsmittelliste aufgeführten Produkte eingesetzt werden. Ausnahmen sind in den Einleitungen der einzelnen Kapitel vermerkt
Liste des intrants 2020 pour l'agriculture biologique en Suisse
La liste des intrants contient tous les produits phytosanitaires, les engrais, les substrats du commerce, les produits de lutte contre les mouches des étables, les agents d'ensilage, les aliments minéraux et complémentaires, les produits pour la désinfection des stabulations et les produits contre les maladies des abeilles autorisés pour l'agriculture biologique. Cette liste est contraignante pour les producteurs de Bio Suisse et Demeter. Sur les fermes Bio Suisse, seuls les produits mentionnés sont autorisés. Les exceptions sont décrites séparément dans les introductions aux différents chapitres